Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
Status:
Terminated
Trial end date:
2018-08-16
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, active control, two-arm parallel, double-blind, monocenter
phase IV clinical trial. The trial compares empagliflozin to glimepiride in patients with
type 2 diabetes mellitus in addition to standard of care treatment.
Patients with type 2 diabetes mellitus who are between 18 and 80 years of age will be
recruited for the clinical trial and randomly allocated to either receive empagliflozin or
glimepiride.
The assumption of the study is that empagliflozin slows down diabetic retinopathy progression
rate and thus a lower microaneurysm formation rate compared to subjects treated with
glimepiride by substantially decreased cellular glucotoxicity will be achieved.